Fig. 4: Comutation plot depicting commonly altered genes in 40/42 (95%) samples that underwent initial next generation sequencing. | npj Breast Cancer

Fig. 4: Comutation plot depicting commonly altered genes in 40/42 (95%) samples that underwent initial next generation sequencing.

From: Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2– breast cancer (LEADER)

Fig. 4

Notably, one patient with MRD did not have significantly overlapping genomic variants and thus is not listed in the above plot. Additional clinical data includes minimal residual disease status, stage, hormone receptor status, prior endocrine therapy duration, and identity of prior endocrine therapy. MRD minimal residual disease, ER estrogen receptor; PR progesterone receptor; ET endocrine therapy.

Back to article page